Chardan Capital analyst Taylor Feehley reiterated a Buy rating on Spring Bank Pharmaceuticals Inc (SBPH) today and set a price target of $25. The company’s shares opened today at $10.29.
According to TipRanks.com, Feehley is a 2-star analyst with an average return of -1.5% and a 40.0% success rate. Feehley covers the Healthcare sector, focusing on stocks such as Evelo Biosciences Inc, Seres Therapeutics, and Synlogic Inc.
Spring Bank Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $26, a 152.7% upside from current levels. In a report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $29 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.95 and a one-year low of $8.14. Currently, Spring Bank Pharmaceuticals Inc has an average volume of 22.15K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spring Bank Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its pipeline include RIG-I & STING Agonists platforms. The company was founded by Douglas J. Jensen and Radhakrishnan P.
